Overall very positive - Avis employé Pharmaceuticals Sales Representative Merck

4,0
1 déc. 2009
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Good work-life balance. Company has moved to reward individual performance. Many benefits if you are able to manage a territory - your manager will leave you alone and not be on your back the whole time. If you were lucky enough to start 10 years ago, then you're a full-time employee with all the benefits/pension etc. If they decide to lay you off, then severance package has been pretty good.

Inconvénients

The whole industry needs to get a backbone and stand up for their right to market medications to customers. They are not allowing reps to develop rapport with physicians essentially by cutting out all the budgets for everything other than 'food'. If you are new, you are most likely going to be on a contract, so - no benefits/pension. With the acquisition of Schering there will be more downsizing. Seems like this is done every year in December. We have moved to multiple products in the bag - I have 4! It makes it very difficult to do your job, when you need to discuss all four products at every visit. You end up spinning your wheels.

Découvrez plus d’avis sur Merck

5,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Excellent company to work with.

Inconvénients

No cons encountered so far

4,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Inconvénients

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Voir les avis par: Utile|Évaluation|Date|Tout